{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:10:59Z","timestamp":1778749859736,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360344"],"award-info":[{"award-number":["82360344"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202401AY070001-247"],"award-info":[{"award-number":["202401AY070001-247"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.prp.2025.156048","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T02:40:18Z","timestamp":1748313618000},"page":"156048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses"],"prefix":"10.1016","volume":"271","author":[{"given":"Zhenghua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.prp.2025.156048_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743):a multicentre, randomized, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.prp.2025.156048_bib2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma,renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prp.2025.156048_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2020.05.023","article-title":"Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells","volume":"146","author":"Otsuka","year":"2020","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.prp.2025.156048_bib4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM):a multicentre, single-arm,phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2025.156048_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211061956","article-title":"Immunotherapy, the promise for present and future of malignant pleural mesothelioma(MPM) treatment","volume":"13","author":"Gounant","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2025.156048_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","article-title":"Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma:an international multicenter study","volume":"10","author":"Brcic","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"10.1016\/j.prp.2025.156048_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"issue":"17","key":"10.1016\/j.prp.2025.156048_bib8","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.3390\/ijms20174182","article-title":"Building a bridge between chemotherapy and immunotherapy in malignant pleural mesothelioma: investigating the effect of chemotherapy on immune checkpoint expression","volume":"20","author":"Marcq","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.prp.2025.156048_bib9","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s11864-023-01148-2","article-title":"Updates in management of malignant pleural mesothelioma","volume":"24","author":"John","year":"2023","journal-title":"Curr. Treat. Option"},{"issue":"2","key":"10.1016\/j.prp.2025.156048_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ijc.27611","article-title":"SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumour activity against malignant pleural mesothelioma","volume":"132","author":"Iwahori","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.prp.2025.156048_bib11","doi-asserted-by":"crossref","first-page":"11248","DOI":"10.3390\/ijms231911248","article-title":"Antagonist of growth hormone-releasing hormone potentiates the antitumour effect of pemetrexed and cisplatin in pleural mesothelioma","volume":"23","author":"Gesmundo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.prp.2025.156048_bib12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/ijc.30228","article-title":"Synergistic antitumour efficacy of immunogenic adenovirus ONCOS-102 (Ad5\/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model","volume":"139","author":"Kuryk","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.prp.2025.156048_bib13","doi-asserted-by":"crossref","first-page":"11949","DOI":"10.3390\/ijms231911949","article-title":"Schedule-dependent treatment increases chemotherapy efficacy in malignant pleural mesothelioma","volume":"23","author":"Karatkevich","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.prp.2025.156048_bib14","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/cancers11101446","article-title":"In vitro characterization of cisplatin and pemetrexed effects in malignant pleural mesothelioma 3D culture phenotypes","volume":"11","author":"Papazoglou Eleftherios","year":"2019","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.prp.2025.156048_bib15","article-title":"T-cell infiltration in matched samples from malignant pleural mesothelioma (MPM) during evolution of disease","volume":"40","author":"Cedres Perez","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.156048_bib16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression:correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2025.156048_bib17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE):results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"15","key":"10.1016\/j.prp.2025.156048_bib18","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1200\/JCO.2021.39.15_suppl.8555","article-title":"Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype","volume":"39","author":"Dagogo-Jack","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.156048_bib19","first-page":"47","article-title":"Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer","volume":"38","author":"Sarabjot","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.prp.2025.156048_bib20","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1158\/1078-0432.CCR-22-0159","article-title":"A paradigm of cancer immunotherapy based on 2-[18 F]FDG and anti-PD-L1 mAb combination to enhance the antitumor effect","volume":"28","author":"Wen","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2025.156048_bib21","article-title":"Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K\/AKT\/PD-L1 axis","volume":"143","author":"Dan","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.prp.2025.156048_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1535-7163.MCT-24-0289","article-title":"Riluzole enhancing anti-PD-1 efficacy by activating cgas\/sting signaling in colorectal cancer","volume":"24","author":"Liang","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.prp.2025.156048_bib23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/cancers12030666","article-title":"Pemetrexed enhances membrane PD-L1 expression and potentiates T-cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small cell lung cancer","volume":"12","author":"Cavazzoni","year":"2020","journal-title":"Cancers"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:26:50Z","timestamp":1778747210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825002419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"alternative-id":["S0344033825002419"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156048","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156048"}}